SINGLE DOMAIN ANTIBODIES AND BIOENGINEERING DRUGS ON THEIR BASIS: NEW OPPORTUNITIES FOR DIAGNOSTICS AND THERAPY
Almost 20 years ago, a unique class of antibodies devoid of L chains was discovered in Camelidae blood serum. Only one variable domain is responsible for antigen recognition in these unusual antibodies. A recombinant protein, which is analogue to such antigen-recognizing variable domain was called t...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists
2016-12-01
|
| Series: | Медицинская иммунология |
| Subjects: | |
| Online Access: | https://www.mimmun.ru/mimmun/article/view/1131 |
| _version_ | 1797197926055804928 |
|---|---|
| author | E. N. Gorshkova E. A. Vasilenko S. V. Tillib I. V. Astrakhantseva |
| author_facet | E. N. Gorshkova E. A. Vasilenko S. V. Tillib I. V. Astrakhantseva |
| author_sort | E. N. Gorshkova |
| collection | DOAJ |
| description | Almost 20 years ago, a unique class of antibodies devoid of L chains was discovered in Camelidae blood serum. Only one variable domain is responsible for antigen recognition in these unusual antibodies. A recombinant protein, which is analogue to such antigen-recognizing variable domain was called the single domain antibody (sdAb), “nanobody” or “nanoantibody”. The single-domain antibodies and their derivatives have been widely used in the field of biology, toxicology and medicine offering new opportunities for diagnosis and treatment of cancer, autoimmune diseases, infectious diseases, and for toxin neutralization. This review focuses on latest researches in the field and concerns some prospectives for creation of nanoantibody-based diagnostic and therapeutic drugs. |
| first_indexed | 2024-03-08T05:49:20Z |
| format | Article |
| id | doaj.art-0d2b367f078848c98022a2764ff53ec5 |
| institution | Directory Open Access Journal |
| issn | 1563-0625 2313-741X |
| language | Russian |
| last_indexed | 2024-04-24T06:51:43Z |
| publishDate | 2016-12-01 |
| publisher | St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists |
| record_format | Article |
| series | Медицинская иммунология |
| spelling | doaj.art-0d2b367f078848c98022a2764ff53ec52024-04-22T13:07:41ZrusSt. Petersburg branch of the Russian Association of Allergologists and Clinical ImmunologistsМедицинская иммунология1563-06252313-741X2016-12-0118650552010.15789/1563-0625-2016-6-505-520866SINGLE DOMAIN ANTIBODIES AND BIOENGINEERING DRUGS ON THEIR BASIS: NEW OPPORTUNITIES FOR DIAGNOSTICS AND THERAPYE. N. Gorshkova0E. A. Vasilenko1S. V. Tillib2I. V. Astrakhantseva3N.I. Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russian FederationN.I. Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russian FederationInstitute of Gene Biology, Russian Academy of Sciences, Moscow, Russian FederationN.I. Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russian FederationAlmost 20 years ago, a unique class of antibodies devoid of L chains was discovered in Camelidae blood serum. Only one variable domain is responsible for antigen recognition in these unusual antibodies. A recombinant protein, which is analogue to such antigen-recognizing variable domain was called the single domain antibody (sdAb), “nanobody” or “nanoantibody”. The single-domain antibodies and their derivatives have been widely used in the field of biology, toxicology and medicine offering new opportunities for diagnosis and treatment of cancer, autoimmune diseases, infectious diseases, and for toxin neutralization. This review focuses on latest researches in the field and concerns some prospectives for creation of nanoantibody-based diagnostic and therapeutic drugs.https://www.mimmun.ru/mimmun/article/view/1131single-domain antibodiesсamel antibodiesnanoantibodiesvhhbi-specific antibodiesbioengineered drugs |
| spellingShingle | E. N. Gorshkova E. A. Vasilenko S. V. Tillib I. V. Astrakhantseva SINGLE DOMAIN ANTIBODIES AND BIOENGINEERING DRUGS ON THEIR BASIS: NEW OPPORTUNITIES FOR DIAGNOSTICS AND THERAPY Медицинская иммунология single-domain antibodies сamel antibodies nanoantibodies vhh bi-specific antibodies bioengineered drugs |
| title | SINGLE DOMAIN ANTIBODIES AND BIOENGINEERING DRUGS ON THEIR BASIS: NEW OPPORTUNITIES FOR DIAGNOSTICS AND THERAPY |
| title_full | SINGLE DOMAIN ANTIBODIES AND BIOENGINEERING DRUGS ON THEIR BASIS: NEW OPPORTUNITIES FOR DIAGNOSTICS AND THERAPY |
| title_fullStr | SINGLE DOMAIN ANTIBODIES AND BIOENGINEERING DRUGS ON THEIR BASIS: NEW OPPORTUNITIES FOR DIAGNOSTICS AND THERAPY |
| title_full_unstemmed | SINGLE DOMAIN ANTIBODIES AND BIOENGINEERING DRUGS ON THEIR BASIS: NEW OPPORTUNITIES FOR DIAGNOSTICS AND THERAPY |
| title_short | SINGLE DOMAIN ANTIBODIES AND BIOENGINEERING DRUGS ON THEIR BASIS: NEW OPPORTUNITIES FOR DIAGNOSTICS AND THERAPY |
| title_sort | single domain antibodies and bioengineering drugs on their basis new opportunities for diagnostics and therapy |
| topic | single-domain antibodies сamel antibodies nanoantibodies vhh bi-specific antibodies bioengineered drugs |
| url | https://www.mimmun.ru/mimmun/article/view/1131 |
| work_keys_str_mv | AT engorshkova singledomainantibodiesandbioengineeringdrugsontheirbasisnewopportunitiesfordiagnosticsandtherapy AT eavasilenko singledomainantibodiesandbioengineeringdrugsontheirbasisnewopportunitiesfordiagnosticsandtherapy AT svtillib singledomainantibodiesandbioengineeringdrugsontheirbasisnewopportunitiesfordiagnosticsandtherapy AT ivastrakhantseva singledomainantibodiesandbioengineeringdrugsontheirbasisnewopportunitiesfordiagnosticsandtherapy |